Lipoprotein(a) as a Predictor of Cardiovascular Disease in a Prospectively Followed Cohort of Patients With Type 1 Diabetes

Kollerits, Barbara; Auinger, Martin; Reisig, Veronika; Kästenbauer, T; Lingenhel, Arno; Irsigler, K; Prager, Rudolf; Kronenberg, Florian

doi:10.2337/dc06-0546

Cited by 23 publications

(18 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of cross-sectional studies [44–52] and prospective studies [23, 40, 53–57] have investigated the relationship between plasma Lp(a) levels and CVD risk in diabetic patients and reported inconsistent results. Table 1 summarizes conflicting results from prospective studies in diabetic patients.…”

Section: Lp(a) and Cvd In Diabetic Patientsmentioning

confidence: 99%

“…By contrast, two prospective studies reported positive associations between Lp(a) levels and risk of CVD in patients with Type 2 diabetes, but the risk ratio for CVD by comparing high and low Lp(a) levels might be overestimated (relative risk [RR]: 7.67 [95% CI: 1.10–53.3] and 6.6 [95% CI: 1.6–26.8]) owing to the small number of cases (n = 8 and 23, respectively) [54, 55]. In 429 consecutive unrelated patients with Type 1 diabetes during the observation period of up to 10.7 years, Kollerits et al reported Lp(a) levels of >30 mg/dl as a strong and independent predictor of CVD (RR: 2.23 [95% CI: 1.28–3.87]) [57]. …”

Section: Lp(a) and Cvd In Diabetic Patientsmentioning

confidence: 99%

“… † This is an updated analysis expanding a previous study conducted by Shai et al [57], which is not included in this table. CHD: Coronary heart disease; CVD: Cardiovascular disease; Lp(a): Lipoprotein(a); RR: Relative risk; SD: Standard deviation. …”

Section: Figurementioning

confidence: 99%

“… † This is an updated analysis expanding a previous study conducted by Shai et al [57], which is not included in this table. …”

Section: Figurementioning

confidence: 99%

See 3 more Smart Citations

Lipoprotein(a) and cardiovascular disease in diabetic patients

2012

Clinical Lipidology

View full text Add to dashboard Cite

Lipoprotein(a) (Lp[a]) is a LDL-like particle consisting of an ApoA moiety linked to one molecule of ApoB100. Recent data from large-scale prospective studies and genetic association studies provide highly suggestive evidence for a potentially causal role of Lp(a) in affecting risk of cardiovascular disease (CVD) in general populations. Patients with Type 2 diabetes display clustered metabolic abnormalities and elevated risk of CVD. Lower plasma Lp(a) levels were observed in diabetic patients in several recent studies. Epidemiology studies of Lp(a) and CVD risk in diabetic patients generated inconsistent results. We recently found that Lp(a)-related genetic markers did not predict CVD in two diabetic cohorts. The current data suggest that Lp(a) may differentially affect cardiovascular risk in diabetic patients and in the general population. More prospective studies, Mendelian randomization analysis and functional studies are needed to clarify the causal relationship of Lp(a) and CVD in diabetic patients.

show abstract

Section: Lp(a) and Cvd In Diabetic Patientsmentioning

confidence: 99%

Section: Lp(a) and Cvd In Diabetic Patientsmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

“… † This is an updated analysis expanding a previous study conducted by Shai et al [57], which is not included in this table. …”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Lipoprotein(a) and cardiovascular disease in diabetic patients

2012

Clinical Lipidology

View full text Add to dashboard Cite

show abstract

“…Elevated Lp(a) levels have generally [20, 21], but not universally [22, 23], been associated with increased CVD risk in both type 1 and type 2 diabetes mellitus. Interestingly, patients with diabetes have been shown to have lower Lp(a) levels in non-diabetics, both in patients with suspected CAD undergoing coronary angiography [22], as well as patients presenting with acute coronary syndromes [24].…”

Section: Lp(a) and Diabetes Mellitusmentioning

confidence: 99%

Lipoprotein(a)

Tsimikas

2016

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of review The purpose of this review is to summarize recent observations on the role of lipoprotein(a) [Lp(a)] as a risk factor mediating cardiovascular disease. Recent findings Lp(a) is a highly prevalent cardiovascular risk factor, with levels >30 mg/dL affecting 20–30% of the global population. Up until now, no specific therapies have been developed to lower Lp(a) levels. Three major levels of evidence support the notion that elevated Lp(a) levels are a causal, independent, genetic risk factor for cardiovascular disease; epidemiologic studies and meta-analyses, genome wide association studies and mendelian randomization studies. Recent studies also have noted that individuals with low levels of Lp(a) are associated with a higher risk of incident type 2 diabetes mellitus, and conversely individuals with high levels have a lower risk, but this association does not appear to be causal. Novel therapies to lower Lp(a) include PCSK9 inhibitors and antisense oligonucleotides directly preventing translation of apolipoprotein(a) mRNA. Summary With this robust and expanding clinical database, a re-awakening of interest in Lp(a) as clinical risk factor is taking place. Trials are underway with novel drugs that substantially lower Lp(a) and may reduce its contribution to cardiovascular disease.

show abstract

Current literature in diabetes

2007

Diabetes Metabolism Res

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of diabetes/metabolism. Each bibliography is divided into 26 sections: 1 Reviews & Symposia; 2 General; 3 Genetics; 4 Epidemiology; 5 Immunology; 6 Obesity; 7 Prediction and Prevention; 8 Intervention: a) General; b) Care; c) Drug Therapy; d)Economics; e) Gene therapy; f) Nursing; g) Nutrition; h) Surgery; i) Transplantation; 9 Pathology and Complications: a) General; b) Cardiovascular; c) Eye disease; d) Gestational and fetal; e) Neurological; f) Podiatrical; g) Renal; 10 Endocrinology & Metabolism; 11 Experimental Studies; 12 Diagnosis and Techniques. Within each section, articles are listed in alphabetical order with respect to author

show abstract

Lipoprotein(a) as a Predictor of Cardiovascular Disease in a Prospectively Followed Cohort of Patients With Type 1 Diabetes

Cited by 23 publications

References 22 publications

Lipoprotein(a) and cardiovascular disease in diabetic patients

Lipoprotein(a) and cardiovascular disease in diabetic patients

Lipoprotein(a)

Current literature in diabetes

Contact Info

Product

Resources

About